What's Happening?
Revel Pharmaceuticals, in collaboration with researchers from Calico and the University of Colorado Anschutz Medical Campus, has published a study in Nature Communications detailing the development of an engineered enzyme called CMLase. This enzyme is capable
of reversing a type of chemical damage known as Nε-carboxymethyl-lysine (CML), which accumulates in long-lived proteins over time. CML is a form of advanced glycation end product (AGE) that forms when sugars react with proteins, similar to the browning of bread. The study demonstrated that CMLase could significantly reduce CML levels in human tissues, including arterial and skin tissues from aged donors, effectively reversing damage that was previously considered permanent.
Why It's Important?
The development of CMLase represents a significant breakthrough in the field of aging research. By reversing protein damage associated with aging, this enzyme could potentially lead to new treatments for age-related conditions and improve the quality of life for the elderly. The ability to reverse such damage challenges long-held assumptions about the permanence of aging-related changes in human tissues. This advancement could pave the way for further research into therapies that target other forms of protein damage, potentially extending human healthspan and lifespan.
What's Next?
Further research and development are needed to explore the full potential of CMLase in clinical settings. Revel Pharmaceuticals plans to continue its work on engineered enzymes to address various types of structural damage associated with aging. The company is supported by grants from the National Institutes of Health and aims to expand its platform to include other forms of oxidative and glycation damage. The next steps will likely involve clinical trials to assess the safety and efficacy of CMLase in humans, which could lead to new therapeutic options for age-related diseases.
